Specialized Pro-Resolving Mediators as Potential Regulators of Inflammatory Macrophage Responses in COVID-19

Balta, Maria G.; Papathanasiou, Evgenia; Christopoulos, Panagiotis

doi:10.3389/fimmu.2021.632238

Cited by 20 publications

(21 citation statements)

References 104 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Severe patients are characterized by a hyper immuno-activation leading generally to respiratory failure, systemic inflammation and multi-organ fibrosis. Markers associated with this acute immune-inflammatory response and severe COVID-19 symptoms could be found among chemicals involved in the cytokine and oxylipin storm [ 1 ].…”

Section: Introductionmentioning

confidence: 99%

MS-based targeted profiling of oxylipins in COVID-19: A new insight into inflammation regulation

Biagini

Franzini

Oliveri

et al. 2022

Free Radical Biology and Medicine

View full text Add to dashboard Cite

The key role of inflammation in COVID-19 induced many authors to study the cytokine storm, whereas the role of other inflammatory mediators such as oxylipins is still poorly understood. IMPRECOVID was a monocentric retrospective observational pilot study with COVID-19 related pneumonia patients (n = 52) admitted to Pisa University Hospital between March and April 2020. Our MS-based analytical platform permitted the simultaneous determination of sixty plasma oxylipins in a single run at ppt levels for a comprehensive characterisation of the inflammatory cascade in COVID-19 patients. The datasets containing oxylipin and cytokine plasma levels were analysed by principal component analysis (PCA), computation of Fisher’s canonical variable, and a multivariate receiver operating characteristic (ROC) curve. Differently from cytokines, the panel of oxylipins clearly differentiated samples collected in COVID-19 wards (n = 43) and Intensive Care Units (ICUs) (n = 27), as shown by the PCA and the multivariate ROC curve with a resulting AUC equal to 0.92. ICU patients showed lower (down to two orders of magnitude) plasma concentrations of anti-inflammatory and pro-resolving lipid mediators, suggesting an impaired inflammation response as part of a prolonged and unsolvable pro-inflammatory status. In conclusion, our targeted oxylipidomics platform helped shedding new light in this field. Targeting the lipid mediator class switching is extremely important for a timely picture of a patient’s ability to respond to the viral attack. A prediction model exploiting selected lipid mediators as biomarkers seems to have good chances to classify patients at risk of severe COVID-19.

show abstract

Section: Introductionmentioning

confidence: 99%

MS-based targeted profiling of oxylipins in COVID-19: A new insight into inflammation regulation

Biagini

Franzini

Oliveri

et al. 2022

Free Radical Biology and Medicine

View full text Add to dashboard Cite

show abstract

“…And because we know that SPMs enhance resolution of that inflammation, to me, there is no reason to not use them. We are seeing some tremendous work being done with SPMs and ω‐3 fatty acids in COVID‐19 to enhance resolution of inflammation, which can often be chronic and last much longer than just the viral activity 5,6 . COVID‐19 is a catabolic illness that is occurring on top of another catabolic disease: his pancreatic cancer.…”

Section: Discussionmentioning

confidence: 99%

“…We are seeing some tremendous work being done with SPMs and ω-3 fatty acids in COVID-19 to enhance resolution of inflammation, which can often be chronic and last much longer than just the viral activity. 5,6 COVID-19 is a catabolic illness that is occurring on top of another catabolic disease: his pancreatic cancer. So he is at very high risk, and I would do everything to give him the best opportunity to heal.…”

Section: Prehabilitation For Surgerymentioning

confidence: 99%

Case presentation and panel discussion: Nutrition issues in cancer

Mundi

Mechanick

Patel

et al. 2021

J Parenter Enteral Nutr

View full text Add to dashboard Cite

Advances in treatment of malignancy including novel pharmacologic therapies and surgical interventions has led to significant improvement in survival. As cancer becomes a chronic disease, nutrition interventions play an increasingly important role in short-and long-term outcomes. The current manuscript presents a case of a 66-yearold male with new diagnosis of pancreatic cancer diagnosed incidentally in the setting of COVID-19. Expert panelists in the field of nutrition discuss optimal strategies for diagnosis of malnutrition along with preoperative, perioperative, and postoperative optimization of nutrition. This discussion focuses on the use of probiotics, immunemodulating nutrition, fish oil, specialized proresolving mediators, and use of enteral and parenteral nutrition support.

show abstract

“…Further research is needed to confirm the role of these novel mediators in hyperinflammatory conditions like cancer and COVID-19. Nonetheless, the direct application of SPMs is currently being studied as a therapeutic option for several diseases in humans, including COVID-19 and cancer [181][182][183].…”

Section: The Application Of Spms In Covid-19 and Cancermentioning

confidence: 99%

COVID-19 and cancer: start the resolution!

Barksdale

Kipper

Tripathy

et al. 2022

Cancer Metastasis Rev

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) due to infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been an ongoing pandemic causing significant morbidity and mortality worldwide. The “cytokine storm” is a critical driving force in severe COVID-19 cases, leading to hyperinflammation, multi-system organ failure, and death. A paradigm shift is emerging in our understanding of the resolution of inflammation from a passive course to an active biochemical process driven by endogenous specialized pro-resolving mediators (SPMs), such as resolvins, protectins, lipoxins, and maresins. SPMs stimulate macrophage-mediated debris clearance and counter pro-inflammatory cytokine production, a process collectively termed as the “resolution of inflammation.” Hyperinflammation is not unique to COVID-19 and also occurs in neoplastic conditions, putting individuals with underlying health conditions such as cancer at elevated risk of severe SARS-CoV-2 infection. Despite approaches to block systemic inflammation, there are no current therapies designed to stimulate the resolution of inflammation in patients with COVID-19 or cancer. A non-immunosuppressive therapeutic approach that reduces the cytokine storm in patients with COVID-19 and cancer is urgently needed. SPMs are potent immunoresolvent and organ-protective lipid autacoids that stimulate the resolution of inflammation, facilitate clearance of infections, reduce thrombus burden, and promote a return to tissue homeostasis. Targeting endogenous lipid mediators, such as SPMs, offers an entirely novel approach to control SARS-CoV-2 infection and cancer by increasing the body’s natural reserve of pro-resolving mediators without overt toxicity or immunosuppression.

show abstract

Specialized Pro-Resolving Mediators as Potential Regulators of Inflammatory Macrophage Responses in COVID-19

Cited by 20 publications

References 104 publications

MS-based targeted profiling of oxylipins in COVID-19: A new insight into inflammation regulation

MS-based targeted profiling of oxylipins in COVID-19: A new insight into inflammation regulation

Case presentation and panel discussion: Nutrition issues in cancer

COVID-19 and cancer: start the resolution!

Contact Info

Product

Resources

About